Publicaciones en las que colabora con Ana Rouzaut Subirá (10)

2013

  1. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model

    Clinical Cancer Research, Vol. 19, Núm. 22, pp. 6151-6162

2012

  1. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression

    Journal of Immunology, Vol. 189, Núm. 9, pp. 4674-4683

  2. The HIF-1α hypoxia response in tumor-infi ltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy

    Cancer Discovery, Vol. 2, Núm. 7, pp. 608-623

2011

  1. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes

    Cancer Research, Vol. 71, Núm. 3, pp. 801-811

  2. Carcinoma-derived Interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation

    PLoS ONE, Vol. 6, Núm. 3

  3. Direct effects of type I interferons on cells of the immune system

    Clinical Cancer Research, Vol. 17, Núm. 9, pp. 2619-2627

  4. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy

    International Journal of Cancer, Vol. 128, Núm. 1, pp. 105-118

2010

  1. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 11, pp. 1621-1631

  2. Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α

    European Journal of Immunology, Vol. 40, Núm. 11, pp. 3054-3063

2008

  1. Polly Matzinger's "danger model" finds its predicted danger-denoting self moieties

    Inmunologia, Vol. 27, Núm. 4, pp. 205-211